# Carcinoma, Renal Cell trials: 226 new since Nov 2024

Updated November 9, 2026.

226 clinical studies in Carcinoma, Renal Cell were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 57 have an industry sponsor and 178 are recruiting or about to. The newest, NCT07925333, was posted on November 9, 2026: Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer (Beth Israel Deaconess Medical Center).

## The full list

New Carcinoma, Renal Cell clinical trials: 226 rows for $11.30, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 9 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/condition/carcinoma-renal-cell

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 226
- Industry sponsored: 57
- Recruiting or not yet: 178
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 226, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07925333 | Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer | Beth Israel Deaconess Medical Center | Phase 2 | Not yet recruiting | Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer) | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925333) |
| November 6, 2026 | NCT07922915 | Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Localized Clear Cell Renal Cell Carcinoma | 24 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922915) |
| November 2, 2026 | NCT07911527 | The Edison™ System for Treatment of Renal Tumors Using Histotripsy (Histo-Renal Trial) | Chinese University of Hong Kong | Not applicable | Not yet recruiting | Renal Tumors | 15 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911527) |
| November 2, 2026 | NCT07909265 | Prospective Study of Cadonilimab With Lenvatinib in Renal Cell Carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Recruiting | Renal Cell Carcinoma (Kidney Cancer), Clear Cell Renal Cell Carcinoma | 54 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909265) |
| October 28, 2026 | NCT07901569 | Habitat Analysis of Tumor Thrombus for Vena Cava Wall Invasion in Renal Cell Carcinoma | Liu Zhuo | Observational | Not yet recruiting | Carcinoma, Renal Cell, Inferior Vena Cava Tumor Thrombus | 273 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901569) |
| October 16, 2026 | NCT07877194 | A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal Cancer | Summit Therapeutics | Phase 2 | Not yet recruiting | Renal Cell Carcinoma, Clear Cell | 100 | China, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877194) |
| October 15, 2026 | NCT07875959 | 18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal Tumors | Peking University First Hospital | Not applicable | Recruiting | Renal Cell Carcinoma (RCC), Renal Pelvic Urothelial Carcinoma | 80 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875959) |
| October 15, 2026 | NCT07875946 | 68Ga- and 18F-CAIX PET Imaging Study | Peking University First Hospital | Early phase 1 | Not yet recruiting | Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Renal Tumor | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875946) |
| October 15, 2026 | NCT07874542 | Plasma DNA Methylation for Preoperative Classification of Renal Masses | RenJi Hospital | Observational | Recruiting | Renal Cell Carcinoma, Benign Renal Mass | 240 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874542) |
| October 13, 2026 | NCT07872553 | A Study of Treatment Delivery Preference In People With Kidney Cancer | Memorial Sloan Kettering Cancer Center | Phase 4 | Recruiting | Renal Cell Carcinoma, Kidney Cancer | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872553) |
| October 13, 2026 | NCT07870746 | Phase 2a Study to Assess Safety and Efficacy of Two 177Lu-TLX250 Dosing Regimens in Advanced Relapsed or Recurrent ccRCC | Telix Pharmaceuticals (Innovations) Pty Limited | Phase 2 | Not yet recruiting | ccRCC, Renal Cell Carcinoma (Kidney Cancer), Renal Cell Carcinoma (RCC), Renal Cell Cancer Metastatic, Renal Cell... | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870746) |
| October 8, 2026 | NCT07865832 | A Study of CA9-Targeted CAR Macrophage Therapy in Advanced Clear Cell Renal Cell Carcinoma | Liangyou Gu | Early phase 1 | Not yet recruiting | Clear Cell Renal Cell Carcinoma | 6 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865832) |
| October 7, 2026 | NCT07863024 | Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET... | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 320 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863024) |
| October 1, 2026 | NCT07853001 | Patient Reported Outcomes and Different Renal Artery Clamping Techniques During Robot Assisted Kidney Resection | Bjarte Almas | Not applicable | Not yet recruiting | Renal Cell Carcinoma (Kidney Cancer) | 130 | Norway | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07853001) |
| October 1, 2026 | NCT07852884 | First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain | Bristol-Myers Squibb | Observational | Active not recruiting | Renal Cell Carcinoma (RCC) | 1,200 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07852884) |
| September 30, 2026 | NCT07848295 | A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 1 | Not yet recruiting | Clear Cell Renal Cell Carcinoma (ccRCC) | 112 | Belgium, France, Germany, Italy, Netherlands, Spain, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848295) |
| September 25, 2026 | NCT07841756 | Federated Learning in Renal Tumor Model | First Affiliated Hospital of Guangxi Medical University | Observational | Not yet recruiting | Renal Tumors | 3,000 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841756) |
| September 24, 2026 | NCT07840001 | Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma | Peter MacCallum Cancer Centre, Australia | Phase 2 | Not yet recruiting | Locally Advanced Clear Cell Renal Cell Carcinoma | 30 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07840001) |
| September 22, 2026 | NCT07833085 | CAIX-targeted PET/CT in Solid Tumors | Zhongnan Hospital | Not applicable | Recruiting | Malignant Solid Tumors, Clear Cell Renal Cell Carcinoma, Lung Cancer (NSCLC), Breast Cancer | 100 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07833085) |
| September 18, 2026 | NCT07828704 | Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA | Henry Ford Health System | Phase 2 | Recruiting | Kidney Cancers | 10 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828704) |
| September 18, 2026 | NCT07827482 | Pretreatment 18F-FDG PET/CT Radiomics for Predicting Response to First-Line Targeted Therapy Plus Immunotherapy in Metastatic Renal Cell... | First Affiliated Hospital of Fujian Medical University | Observational | Completed | Metastatic Renal Cell Carcinoma | 228 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07827482) |
| September 14, 2026 | NCT07816770 | MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas | Fudan University | Phase 2 | Not yet recruiting | Metastatic Non-Clear Cell Renal Cell Carcinoma, Metastatic Renal Medullary Carcinomas | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07816770) |
| September 4, 2026 | NCT07805122 | Intensified Monitoring of PhArmacology of Cabozantinib as a Tool for Toxicity Management in Patients With Renal Cell Carcinoma | Centro di Riferimento Oncologico - Aviano | Not applicable | Recruiting | Renal Cell Carcinoma | 216 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805122) |
| September 3, 2026 | NCT07803315 | Hyperspectral Imaging in Robot-Assisted Partial Nephrectomy | University of Leipzig | Observational | Recruiting | Kidney Neoplasm, Renal Mass up to 7cm | 60 | Germany | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07803315) |
| August 20, 2026 | NCT07776717 | TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal... | Fudan University | Phase 2 | Not yet recruiting | Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07776717) |
| August 18, 2026 | NCT07770802 | Clinical Study of HS-IT101 Injection in the Treatment of Advanced Renal Cancer(FASTIL-Renal01) | Hangzhou Huasai Biomedicine Co., Ltd. | Phase 1 | Recruiting | Clear Cell Renal Cell Carcinoma | 15 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770802) |
| August 17, 2026 | NCT07768306 | Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in... | Norroy Bioscience Co., LTD | Phase 1 | Not yet recruiting | Clear Cell Renal Cell Carcinoma (ccRCC) | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07768306) |
| August 7, 2026 | NCT07753343 | Identification and Description of Patients With High-risk Non Metastatic RCC | University Hospital, Bordeaux | Observational | Recruiting | Renal Cell Carcinoma | 6,109 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07753343) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| August 6, 2026 | NCT07748988 | Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma | Vanderbilt-Ingram Cancer Center | Phase 1 | Recruiting | Refractory Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | 12 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748988) |
| August 4, 2026 | NCT07743749 | An MRI-Based Study of Intelligent Pathological Subtyping and Grading of Renal Tumors | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Observational | Recruiting | Renal Tumor, Kidney Neoplasm | 900 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743749) |
| July 21, 2026 | NCT07716735 | Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney... | Jonsson Comprehensive Cancer Center | Phase 1 | Not yet recruiting | Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma... | 18 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07716735) |
| July 20, 2026 | NCT07715565 | Ipilimumab N01 Plus Sintilimab and Lenvatinib as First-line Therapy for Locally Advanced or Metastatic TFE3-Rearranged Renal Cell... | West China Hospital | Phase 2 | Not yet recruiting | Renal Cell Carcinoma (Kidney Cancer), Immunotherapy, Molecular Targeted Therapy | 66 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715565) |
| July 20, 2026 | NCT07714018 | Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active... | Roswell Park Cancer Institute | Not applicable | Recruiting | Renal Cell Carcinoma (RCC) | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714018) |
| July 15, 2026 | NCT07704970 | QLESP Block for Pain Control in Robotic Partial Nephrectomy | Huazhong University of Science and Technology | Not applicable | Recruiting | Renal Cell Carcinoma (Kidney Cancer), Postoperative Pain, Nerve Block | 120 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07704970) |
| July 13, 2026 | NCT07697417 | Multimodal Prediction of Postoperative Prognosis After Partial Nephrectomy for Endophytic Renal Cell Carcinoma | Tianjin Medical University Second Hospital | Observational | Active not recruiting | Renal Cell Carcinoma, Kidney Neoplasms, Endophytic Renal Tumor, Postoperative Renal Function, Partial Nephrectomy... | 406 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07697417) |
| July 8, 2026 | NCT07689812 | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI)... | Natera, Inc. | Not applicable | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma)... | 920 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689812) |
| July 8, 2026 | NCT07689240 | Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma | National Cancer Institute (NCI) | Phase 3 | Not yet recruiting | Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8 | 400 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07689240) |
| July 7, 2026 | NCT07688187 | A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma | PeptiDream Inc. | Phase 1 | Recruiting | Clear Cell Renal Cell Carcinoma | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07688187) |
| July 7, 2026 | NCT07686744 | Neoantigen Peptide Vaccine Plus Pembrolizumab in Renal Cell Carcinoma | Jian Lin | Phase 1 | Not yet recruiting | Renal Cell Carcinoma, Advanced, Recurrent, Refractory | 8 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07686744) |
| July 2, 2026 | NCT07680556 | Promoting Response to IMmunotherapy by Exercise in Patients With Advanced Renal Cell Carcinoma | Radboud University Medical Center | Not applicable | Recruiting | Oncology | 30 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07680556) |
| June 18, 2026 | NCT07657325 | Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk Recurrent Renal Carcinoma | Tianjin Medical University Second Hospital | Observational | Recruiting | Renal Cell Carcinoma (RCC) | 110 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07657325) |
| June 15, 2026 | NCT07647744 | To Evaluate the Safety and Tolerability of Anti-Human CD70 T-Cell Injection in Subjects With Advanced/Metastatic Renal Cancer | Hrain Biotechnology Co., Ltd. | Phase 1 | Recruiting | Renal Cell Carcinoma (RCC) | 18 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07647744) |
| June 12, 2026 | NCT07645742 | Pilot Study of Intermittent Fasting With Immune Checkpoint Inhibitors | West Virginia University | Not applicable | Not yet recruiting | Cancer (Advanced Stage) | 90 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645742) |
| June 9, 2026 | NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors | VM Discovery, Inc. | Phase 1/2 | Recruiting | Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC), Nonsmall Cell Lung Cancer... | 111 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636785) |
| June 9, 2026 | NCT07636148 | Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance | Mark C Burgmans, MD PhD | Observational | Recruiting | Liver Cancer (Primary and Metastatic), Lung Cancer (Diagnosis), Bone Cancer Metastatic, Bone Cancer Tumor, Kidney... | 2,000 | France, Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636148) |
| June 4, 2026 | NCT07627464 | Anlotinib + Benmelstobart vs Surgery for Patients With Localized Renal Cell Carcinoma Scheduled to Undergo Partial Nephrectomy | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Renal Cell Carcinoma (RCC) | 144 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07627464) |
| June 3, 2026 | NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | Huahui Health | Phase 1 | Recruiting | Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Head and Neck Squamous Cell... | 299 | Australia, China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623369) |
| June 2, 2026 | NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | Exelixis | Phase 3 | Enrolling by invitation | Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)... | 5,000 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07620574) |
| May 22, 2026 | NCT07602101 | Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma | RenJi Hospital | Phase 2 | Not yet recruiting | Clear Cell Renal Cell Carcinoma | 33 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602101) |
| May 18, 2026 | NCT07594106 | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic... | Regeneron Pharmaceuticals | Phase 1/2 | Recruiting | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | 265 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594106) |
| May 18, 2026 | NCT07593040 | Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma | Vall d'Hebron Institute of Oncology | Phase 2 | Not yet recruiting | Renal Cell Carcinoma | 150 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07593040) |
| May 11, 2026 | NCT07578025 | Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy | City of Hope Medical Center | Phase 2 | Not yet recruiting | Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | 34 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07578025) |
| May 8, 2026 | NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical... | 50 | Uganda | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07576725) |
| May 6, 2026 | NCT07571551 | Perioperative Trial With IO/TKI for Multi-stage Clear Cell Renal Cell Carcinoma | Jinling Hospital, China | Phase 2 | Recruiting | Clear Cell RCC | 75 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07571551) |
| May 4, 2026 | NCT07564232 | Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Clear Cell Renal Cell Carcinoma | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07564232) |
| April 29, 2026 | NCT07557225 | 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors | Peking University First Hospital | Not applicable | Recruiting | Clear Cell Renal Cell Cancer (ccRCC), Urothelial Carcinoma (UC), Colorectal Cancer, Cervical Cancer, Ovarian Cancer... | 200 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07557225) |
| April 29, 2026 | NCT07555210 | Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy | Jessica Mezzanotte Sharpe | Not applicable | Recruiting | Breast Cancer (Triple Negative Breast Cancer (TNBC)), Renal Cell Carcinoma (Kidney Cancer), Melanoma (Skin Cancer)... | 25 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555210) |
| April 24, 2026 | NCT07551349 | Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell Carcinoma | Beijing Biotech | Phase 1/2 | Recruiting | Advanced or Metastatic Clear Cell Renal Cell Carcinoma | 36 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07551349) |
| April 20, 2026 | NCT07540260 | CAIX PET/ CT Guided Radiation Therapy in CcRCC. | Peking University First Hospital | Not applicable | Recruiting | Radiation Therapy, Metastatic Renal Cancer, Recurrent Renal Cell Cancer | 70 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07540260) |
| April 8, 2026 | NCT07517198 | Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | Phase 1 | Recruiting | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin... | 40 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07517198) |
| April 8, 2026 | NCT07516366 | Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell... | National Cancer Institute (NCI) | Phase 2 | Recruiting | Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV... | 16 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516366) |
| April 3, 2026 | NCT07510334 | VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma | Mayo Clinic | Phase 2 | Recruiting | Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC... | 18 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510334) |
| March 30, 2026 | NCT07500831 | Fasting-Mimicking Diet Combined With IO-TKI Combination Therapy in Patients With Metastatic Renal Cell Carcinoma | Qilu Hospital of Shandong University | Not applicable | Not yet recruiting | Carcinoma, Renal Cell, Metastatic Renal Cell Carcinoma, Advanced Renal Cell Carcinoma | 43 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07500831) |
| March 30, 2026 | NCT07500805 | UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma | UTC Therapeutics Inc. | Phase 1 | Not yet recruiting | CD70-positive Advanced Renal Clear Cell Carcinoma | 21 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07500805) |
| March 27, 2026 | NCT07497958 | Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial Nephrectomy | Sun Yat-sen University | Not applicable | Not yet recruiting | Renal Cell Carcinoma (RCC), Renal Function Abnormal | 174 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07497958) |
| March 27, 2026 | NCT07494435 | Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC | Zhejiang Haichang Biotech Co., Ltd. | Phase 2 | Not yet recruiting | Hepato Cellular Carcinoma (HCC), Renal Cell Cancer | 230 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07494435) |
| March 24, 2026 | NCT07489495 | A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Carcinoma, Renal Cell | 758 | Argentina, Australia, Brazil, Canada, Chile, Czechia, Denmark, France, Germany... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489495) |
| March 23, 2026 | NCT07488572 | Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI... | Sun Yat-sen University | Phase 2 | Enrolling by invitation | Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07488572) |
| March 20, 2026 | NCT07485114 | Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung... | Daniel Keizman | Observational | Recruiting | Renal Cell Carcinoma (Kidney Cancer), Non Small Cell Lung Cancer, Hepatocellular Carcinoma, Transitional Cell Carcinoma | 300 | Israel | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07485114) |
| March 18, 2026 | NCT07480044 | A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly Patients After... | Zhejiang University | Not applicable | Not yet recruiting | Postoperative Delirium (POD), Prostate Cancer, Kidney Tumor | 220 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07480044) |
| March 13, 2026 | NCT07470840 | SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma | Fujian Cancer Hospital | Phase 2 | Not yet recruiting | Locally Advanced or Metastatic Renal Cell Carcinoma | 27 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07470840) |
| March 13, 2026 | NCT07469683 | An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib... | Yonsei University | Phase 2 | Recruiting | Clear Cell Renal Cell Carcinoma, Neoplasms, Malignant Neoplasms, Malignant Neoplasm of Kidney, Except Renal Pelvis | 78 | South Korea | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07469683) |
| March 12, 2026 | NCT07465458 | Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients | Humanitas Hospital, Italy | Observational | Not yet recruiting | Renal Carcinoma | 226 | Italy, Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07465458) |
| March 10, 2026 | NCT07461090 | Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis | Menoufia University | Not applicable | Recruiting | Nonfunctioning Kidney, Renal Cell Carcinoma (RCC) | 60 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07461090) |
| March 10, 2026 | NCT07460206 | Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment | Gruppo Oncologico Italiano di Ricerca Clinica | Phase 2 | Not yet recruiting | ccRCC | 108 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07460206) |
| February 27, 2026 | NCT07436416 | Circulating and Urinary Exosomal miRNA as Predictors of Treatment Response in Advanced Kidney Cancer | Institute of Oncology Ljubljana | Not applicable | Completed | Renal Cell Carcinoma | 91 | Slovenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07436416) |
| February 19, 2026 | NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | Compass Therapeutics | Phase 1 | Recruiting | Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC) | 70 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07419841) |
| February 12, 2026 | NCT07406646 | Circulating and Urinary Exosomal miRNA in Advanced Kidney Cancer (EXO-RENAL1) | Institute of Oncology Ljubljana | Not applicable | Completed | Renal Cell Carcinoma, Advanced Kidney Cancer | 91 | Slovenia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07406646) |
| February 12, 2026 | NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study | OHSU Knight Cancer Institute | Phase 4 | Recruiting | Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma... | 160 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07405086) |
| February 11, 2026 | NCT07402109 | CBCT Guided Markerless SBRT for Renal Cell Cancer | Erasmus Medical Center | Not applicable | Recruiting | Renal Cell Carcinoma (RCC) | 40 | Netherlands | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07402109) |
| February 9, 2026 | NCT07397611 | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC | Dana-Farber Cancer Institute | Phase 2 | Recruiting | Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Renal Carcinoma | 32 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07397611) |
| February 5, 2026 | NCT07389629 | Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC | Sun Yat-sen University | Phase 2 | Recruiting | Iparomlimab and Tuvonralimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy | 25 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07389629) |
| February 4, 2026 | NCT07386158 | Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC | Sun Yat-sen University | Phase 2 | Recruiting | Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC), Neoadjuvant Therapy | 21 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07386158) |
| February 3, 2026 | NCT07383441 | Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | SWOG Cancer Research Network | Phase 3 | Recruiting | Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC... | 718 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07383441) |
| January 27, 2026 | NCT07369505 | Sapu003 in Advanced mTOR-sensitive Solid Tumors | SAPU NANO (US) LLC | Phase 1 | Recruiting | Breast Cancer Metastatic, Renal Cell Carcinoma (RCC), Neuroendocrine Tumors, Tuberous Sclerosis Complex (TSC)... | 27 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07369505) |
| January 20, 2026 | NCT07351266 | Multi-omics Analysis of Renal Cell Carcinoma Mechanisms; Drug Sensitivity Testing in Patient-Derived Cell-based Microtumors | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Observational | Not yet recruiting | Renal Cell Carcinoma (Kidney Cancer) | 10 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07351266) |
| January 16, 2026 | NCT07346404 | Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma | Assistance Publique - Hôpitaux de Paris | Phase 2 | Not yet recruiting | Renal Cell Carcinoma | 50 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07346404) |
| January 12, 2026 | NCT07332923 | Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning | First Affiliated Hospital of Fujian Medical University | Observational | Active not recruiting | Renal Clear Cell Carcinoma, HIF-2α, Radiomics, Nomogram | 500 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07332923) |
| January 8, 2026 | NCT07326280 | The Cold Ischemia Robot-assisted Partial Nephrectomy | Sun Yat-sen University | Not applicable | Recruiting | Renal Cell Carcinoma, Renal Function Abnormal | 310 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07326280) |
| January 6, 2026 | NCT07321197 | Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal Cell Carcinoma (T-LND RCC) | Tianjin Medical University Second Hospital | Not applicable | Recruiting | Renal Cell Carcinoma (Kidney Cancer) | 220 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07321197) |
| December 24, 2025 | NCT07301827 | Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not applicable | Recruiting | Renal Cell Carcinoma | 66 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301827) |
| December 23, 2025 | NCT07300241 | Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma | Neomorph, Inc | Phase 1 | Recruiting | Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic, ccRCC... | 30 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07300241) |
| December 22, 2025 | NCT07297667 | GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours | Canadian Cancer Trials Group | Phase 1 | Recruiting | Alveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer | 30 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07297667) |
| December 19, 2025 | NCT07294859 | Contrast-enhanced Ultrasound and Super-resolution Imaging Predict Renal Function Outcome After Nephrectomy | Jinling Hospital, China | Observational | Recruiting | Nephrectomy, Renal Cell Cancer, AKI - Acute Kidney Injury | 285 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07294859) |
| December 19, 2025 | NCT07293351 | A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With... | Bristol-Myers Squibb | Phase 1/2 | Recruiting | Advanced Renal Cell Carcinoma (RCC) | 474 | Argentina, Australia, Canada, Chile, China, Colombia, Czechia, Finland, France... | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07293351) |
| December 16, 2025 | NCT07285044 | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment... | Mayo Clinic | Phase 2 | Recruiting | Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma... | 27 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285044) |
| December 16, 2025 | NCT07284953 | A Novel Haemostatic Agent for Robotic Partial Nephrectomy | The Royal Wolverhampton Hospitals NHS Trust | Not applicable | Withdrawn | Kidney Cancer, Renal Cell Carcinoma | 0 | United Kingdom | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07284953) |
| December 11, 2025 | NCT07277972 | Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear... | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | RCC, Renal Cell Cancer | 36 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07277972) |
| December 1, 2025 | NCT07256223 | A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread | Fudan University | Phase 2 | Not yet recruiting | Clear Cell Renal Cell Cancer (ccRCC), Liver Metastasis | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07256223) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Sun Yat-sen University | 8 | November 6, 2026 |
| M.D. Anderson Cancer Center | 7 | May 4, 2026 |
| Peking University First Hospital | 5 | October 15, 2026 |
| First Affiliated Hospital of Fujian Medical University | 5 | September 18, 2026 |
| Tianjin Medical University Second Hospital | 5 | July 13, 2026 |
| City of Hope Medical Center | 5 | May 11, 2026 |
| Jinling Hospital, China | 5 | May 6, 2026 |
| RenJi Hospital | 4 | October 15, 2026 |
| Bristol-Myers Squibb | 4 | October 1, 2026 |
| Fudan University | 4 | September 14, 2026 |
| Merck Sharp & Dohme LLC | 4 | March 24, 2026 |
| AstraZeneca | 4 | August 15, 2025 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 3 | November 2, 2026 |
| Memorial Sloan Kettering Cancer Center | 3 | October 13, 2026 |
| Telix Pharmaceuticals (Innovations) Pty Limited | 3 | October 13, 2026 |
| Mayo Clinic | 3 | April 3, 2026 |
| Shao Pengfei | 3 | June 13, 2025 |
| Regeneron Pharmaceuticals | 2 | October 7, 2026 |
| National Cancer Institute (NCI) | 2 | July 8, 2026 |
| Tianjin Medical University Cancer Institute and Hospital | 2 | June 4, 2026 |

## By phase

| Phase | New trials | Latest |
| --- | --- | --- |
| [Phase 2](https://specstream.ai/data/clinical-trials/phase/phase-2) | 61 | November 9, 2026 |
| [Observational](https://specstream.ai/data/clinical-trials/phase/observational) | 47 | October 28, 2026 |
| [Not applicable](https://specstream.ai/data/clinical-trials/phase/not-applicable) | 44 | November 2, 2026 |
| [Phase 1](https://specstream.ai/data/clinical-trials/phase/phase-1) | 35 | September 30, 2026 |
| [Phase 1/2](https://specstream.ai/data/clinical-trials/phase/phase-1-2) | 18 | October 7, 2026 |
| [Phase 3](https://specstream.ai/data/clinical-trials/phase/phase-3) | 11 | July 8, 2026 |
| [Phase 4](https://specstream.ai/data/clinical-trials/phase/phase-4) | 5 | October 13, 2026 |
| [Early phase 1](https://specstream.ai/data/clinical-trials/phase/early-phase-1) | 4 | October 15, 2026 |
| [Phase 2/3](https://specstream.ai/data/clinical-trials/phase/phase-2-3) | 1 | July 25, 2025 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 77 | November 9, 2026 |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 77 | November 2, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 17 | September 30, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 14 | September 24, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 12 | October 1, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 12 | September 30, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 9 | March 24, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 8 | September 30, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 7 | March 24, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 6 | September 30, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 6 | March 24, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 5 | March 24, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 5 | March 24, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 4 | March 24, 2026 |
| [Chile](https://specstream.ai/data/clinical-trials/country/chile) | 4 | March 24, 2026 |
| [Czechia](https://specstream.ai/data/clinical-trials/country/czechia) | 4 | March 24, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 4 | December 19, 2025 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 3 | September 30, 2026 |
| [Argentina](https://specstream.ai/data/clinical-trials/country/argentina) | 3 | March 24, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 3 | March 24, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 3 | March 24, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 3 | March 10, 2026 |
| [Greece](https://specstream.ai/data/clinical-trials/country/greece) | 2 | March 24, 2026 |
| [Slovenia](https://specstream.ai/data/clinical-trials/country/slovenia) | 2 | February 27, 2026 |
| [Ireland](https://specstream.ai/data/clinical-trials/country/ireland) | 2 | December 19, 2025 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).